CCM
RARE icon

Cinctive Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Cinctive Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-18,731
Closed -$681K – 497
2025
Q2 		$681K Sell
18,731
-58,530
-76% -$2.11M 0.04% 298
2025
Q1 		$2.8M Buy
77,261
+14,301
+23% +$595K 0.21% 137
2024
Q4 		$2.65M Buy
62,960
+47,058
+296% +$2.33M 0.13% 195
2024
Q3 		$883K Sell
15,902
-110,779
-87% -$5.64M 0.05% 298
2024
Q2 		$5.21M Buy
126,681
+14,930
+13% +$637K 0.25% 138
2024
Q1 		$5.22M Buy
111,751
+13,700
+14% +$646K 0.24% 127
2023
Q4 		$4.69M Buy
+98,051
New +$3.8M 0.31% 107
2022
Q2 		– Sell
-89,692
Closed -$6.51M – 616
2022
Q1 		$6.51M Buy
89,692
+15,936
+22% +$1.11M 0.24% 140
2021
Q4 		$6.2M Buy
73,756
+14,927
+25% +$1.21M 0.27% 115
2021
Q3 		$5.31M Buy
58,829
+30,118
+105% +$2.72M 0.26% 124
2021
Q2 		$2.74M Buy
28,711
+13,756
+92% +$1.43M 0.13% 233
2021
Q1 		$1.7M Buy
14,955
+9,008
+151% +$1.23M 0.1% 280
2020
Q4 		$823K Sell
5,947
-28,102
-83% -$3.33M 0.07% 286
2020
Q3 		$2.8M Sell
34,049
-4,059
-11% -$336K 0.25% 163
2020
Q2 		$2.98M Sell
38,108
-21,925
-37% -$1.45M 0.34% 121
2020
Q1 		$2.67M Sell
60,033
-73,568
-55% -$3.82M 0.59% 64
2019
Q4 		$5.71M Buy
+133,601
New +$5.51M 0.6% 74

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Cinctive Capital Management's RARE Position: Q3 2025 in Review

Cinctive Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2025, closing a stake of 18,731 shares — an estimated $681K sold.

Cinctive Capital Management first reported a position in RARE in Q4 2019 and held it in 17 quarters. The position peaked at $6.51M in Q1 2022. 303 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

  • Cinctive Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • Cinctive Capital Management sold 18,731 Ultragenyx Pharmaceutical shares in Q3 2025, an estimated $681K.
  • Cinctive Capital Management first reported a position in Ultragenyx Pharmaceutical in Q4 2019 and held it in 17 quarters.
  • Cinctive Capital Management's Ultragenyx Pharmaceutical position peaked at $6.51M in Q1 2022.
  • 303 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on Cinctive Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.